Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + trastuzumab + pyrotinib + letrozole neoadjuvant study in ER-positive/HER2-positive early breast cancer
ChiCTR2200058949Phase 4Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib, trastuzumab, pyrotinib and letrozole in breast cancer, sponsored by Yunnan Cancer Hospital. Primary endpoint: Pathological complete response rate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058949.